JP2022530037A5 - - Google Patents
Info
- Publication number
- JP2022530037A5 JP2022530037A5 JP2021562962A JP2021562962A JP2022530037A5 JP 2022530037 A5 JP2022530037 A5 JP 2022530037A5 JP 2021562962 A JP2021562962 A JP 2021562962A JP 2021562962 A JP2021562962 A JP 2021562962A JP 2022530037 A5 JP2022530037 A5 JP 2022530037A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- tcr
- nucleic acid
- acid molecule
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836977P | 2019-04-22 | 2019-04-22 | |
| US62/836,977 | 2019-04-22 | ||
| US201962943679P | 2019-12-04 | 2019-12-04 | |
| US62/943,679 | 2019-12-04 | ||
| PCT/US2020/029344 WO2020219563A1 (en) | 2019-04-22 | 2020-04-22 | Compositions and methods for tcr reprogramming using fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022530037A JP2022530037A (ja) | 2022-06-27 |
| JP2022530037A5 true JP2022530037A5 (https=) | 2023-04-28 |
Family
ID=72941760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562962A Pending JP2022530037A (ja) | 2019-04-22 | 2020-04-22 | 融合タンパク質を使用するｔｃｒ再プログラミングのための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220362295A1 (https=) |
| EP (1) | EP3959322A4 (https=) |
| JP (1) | JP2022530037A (https=) |
| CN (1) | CN114258430A (https=) |
| AU (1) | AU2020262111A1 (https=) |
| CA (1) | CA3137519A1 (https=) |
| WO (1) | WO2020219563A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| WO2017222911A1 (en) | 2016-06-20 | 2017-12-28 | The Board Of Trustees Of The Leland Stanford Junior University | Circular rnas and their use in immunomodulation |
| US20220288176A1 (en) * | 2019-08-28 | 2022-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Circular rna modification and methods of use |
| KR20230028375A (ko) | 2020-06-25 | 2023-02-28 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 원형 rna 번역을 구동하는 유전 요소와 이를 사용하는 방법 |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| EP3964585A1 (en) * | 2020-09-03 | 2022-03-09 | Miltenyi Biotec B.V. & Co. KG | Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets |
| CA3197316A1 (en) * | 2020-09-29 | 2022-04-07 | NeuExcell Therapeutics Inc. | Neurod1 and dlx2 vector |
| CN114516913B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测试剂盒 |
| WO2022116528A1 (zh) * | 2020-12-04 | 2022-06-09 | 苏州科锐迈德生物医药科技有限公司 | 环状rna、包含环状rna的疫苗及用于检测新型冠状病毒中和抗体的试剂盒 |
| CN112481289B (zh) | 2020-12-04 | 2023-06-27 | 苏州科锐迈德生物医药科技有限公司 | 一种转录环状rna的重组核酸分子及其在蛋白表达中的应用 |
| JPWO2023027082A1 (https=) * | 2021-08-23 | 2023-03-02 | ||
| WO2023070043A1 (en) * | 2021-10-20 | 2023-04-27 | Yale University | Compositions and methods for targeted editing and evolution of repetitive genetic elements |
| JP2025504398A (ja) * | 2022-01-10 | 2025-02-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｕｃ１６キメラ抗原受容体 |
| CN114606263B (zh) * | 2022-05-11 | 2022-09-06 | 上海优替济生生物医药有限公司 | 分离的核酸分子及其用途 |
| JP2025530303A (ja) * | 2022-09-10 | 2025-09-11 | エクスクルサーク・（スージョウ）・バイオメディカル・カンパニー・リミテッド | 環状ｒｎａ及びその調製方法 |
| CN116411023B (zh) * | 2023-02-24 | 2025-08-12 | 北京大学人民医院 | 一种新型环状rna成环序列构建car-t细胞及在治疗小细胞肺癌中的应用 |
| WO2024215872A1 (en) * | 2023-04-11 | 2024-10-17 | The Regents Of The University Of California | Human t cell receptors targeting tumor-enhanced splicing epitopes on hla-a*02:01 for small cell carcinoma |
| WO2024236366A2 (en) * | 2023-05-12 | 2024-11-21 | Sekkei Bio Private Limited | Design and method of generating scarless circular rna |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015034925A1 (en) * | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| PL3298033T5 (pl) * | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| ES2891578T3 (es) * | 2016-04-01 | 2022-01-28 | Kite Pharma Inc | Antígeno quimérico y receptores de células T y métodos de uso |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| WO2018232020A1 (en) * | 2017-06-13 | 2018-12-20 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2019222275A2 (en) * | 2018-05-14 | 2019-11-21 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using inducible fusion proteins |
-
2020
- 2020-04-22 US US17/604,857 patent/US20220362295A1/en not_active Abandoned
- 2020-04-22 JP JP2021562962A patent/JP2022530037A/ja active Pending
- 2020-04-22 AU AU2020262111A patent/AU2020262111A1/en not_active Abandoned
- 2020-04-22 EP EP20794866.2A patent/EP3959322A4/en not_active Withdrawn
- 2020-04-22 CN CN202080045885.0A patent/CN114258430A/zh active Pending
- 2020-04-22 WO PCT/US2020/029344 patent/WO2020219563A1/en not_active Ceased
- 2020-04-22 CA CA3137519A patent/CA3137519A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022530037A5 (https=) | ||
| US12466885B2 (en) | Bispecific chimeric antigen receptors and encoding polynucleotides, vectors and cells thereof | |
| JP7320560B2 (ja) | 治療免疫細胞の有効性を改良するための方法 | |
| TWI905076B (zh) | 非複製勝任型重組反轉錄病毒顆粒及其用途 | |
| JP6775515B2 (ja) | トランスポザーゼポリペプチド及びその使用 | |
| EP4303233A1 (en) | Targeted protein degradation system and use thereof | |
| CA3139032A1 (en) | Circular rna compositions and methods | |
| CN114258430A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| AU2018202294A1 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| CN115151275A (zh) | 用于向细胞递送核酸的组合物和方法 | |
| JP2021515598A5 (https=) | ||
| CN107002084A (zh) | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 | |
| JP2016539929A (ja) | 免疫療法のためのポリクローナルγδＴ細胞 | |
| JP2025010249A (ja) | 二量体形成剤調節性免疫受容体複合体 | |
| JP2024036482A (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| JP7778130B2 (ja) | 組換えｅｒＩＬ－１５ ＮＫ細胞 | |
| CN110914431A (zh) | 经人工操纵的免疫细胞 | |
| US20230348556A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| CN113891718A (zh) | 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞 | |
| CN114514247A (zh) | Car-cd123载体及其用途 | |
| US12606603B2 (en) | IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy | |
| US20250340599A1 (en) | Targeted protein degradation system and use thereof | |
| HK40086170A (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| KR20240094169A (ko) | B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도 | |
| HK40117709A (zh) | 利用无疤痕环状mrna工程化改造细胞的方法及其用途 |